Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Net Cash Flow: 2023-2024

Historic Net Cash Flow for Inhibrx Biosciences (INBX) over the last 2 years, with Dec 2024 value amounting to -$125.3 million.

  • Inhibrx Biosciences' Net Cash Flow fell 9.67% to -$33.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.2 million, marking a year-over-year increase of 69.33%. This contributed to the annual value of -$125.3 million for FY2024, which is 3187.66% down from last year.
  • According to the latest figures from FY2024, Inhibrx Biosciences' Net Cash Flow is -$125.3 million, which was down 3,187.66% from $4.1 million recorded in FY2023.
  • In the past 5 years, Inhibrx Biosciences' Net Cash Flow ranged from a high of $4.1 million in FY2023 and a low of -$125.3 million during FY2024.
  • Moreover, its 2-year median value for Net Cash Flow was -$60.6 million (2023), whereas its average is -$60.6 million.
  • Data for Inhibrx Biosciences' Net Cash Flow shows a maximum YoY tumbled of 3,187.66% (in 2024) over the last 5 years.
  • Over the past 2 years, Inhibrx Biosciences' Net Cash Flow (Yearly) stood at $4.1 million in 2023, then slumped by 3,187.66% to -$125.3 million in 2024.